Seoochre

The pharmaceutical industry is expected to be worth $1.5 trillion by 2023, and the field of pharmacovigilance plays a crucial role in ensuring the safety of drugs. Artificial Intelligence (AI) and Machine Learning (ML) models are being applied to improve the pharmacovigilance process, including case intake using Optical Character Recognition (OCR) and Natural Language Processing (NLP), natural language generation (NLG) for narrative writing, robotic process automation (RPA) for dynamic case workflow, AI-based signal detection

The global pharmaceutical industry is currently facing many, wide ranging, challenges, including an aging population, increased life expectancy, a rise in chronic conditions, reduced funding for treatments, reduced numbers of clinical staff, the ever increasing cost of drug development and raw materials, and supply chain issues. Consequently, the pharmaceutical industry is increasingly looking at how a wealth of data, including compound libraries, trial data, and patient data, can be used and reused by artificial intelligence (“AI”) to alleviate these challenges and improve patient care.

New technologies, advanced software systems, and the integration of IT within the pharma supply chain are increasingly playing a pivotal part in protecting pharmaceutical payloads worldwide.

Maintaining end-to-end pharma supply chain integrity is critical to mitigate risks within the pharma-logistics cool chain and better ensure the safe and secure transportation of health-giving and life-saving pharmaceutical products.

The global life sciences industry faces a number of complex challenges: protecting the integrity of their temperature-sensitive high-value payloads while mitigating cost

Artificial Intelligence (AI) and machine learning-based technologies have the potential to transform healthcare because they offer new and important insights derived from the vast amount of data generated during the delivery of healthcare every day. The capacity of AI to learn from real-world feedback and improve its performance makes this technology uniquely suited as Software as a Medical Device (SaMD) and is responsible for it being a rapidly expanding area of research and development. Clinical pharmacy practice may undergo major change due to the implementation of this technology.

In the ever-evolving realm of pharmaceutical research and development (R&D), the powerful wave of digitalization is restructuring conventional methodologies and paving the way for a novel era of ingenuity and streamlined processes. Termed digital transformation, this profound shift entails the strategic infusion of cutting-edge information technologies into established drug discovery and development procedures. Leading this revolution are technologies like big data analytics, artificial intelligence (AI), blockchain, and telemedicine. Digital transformation signifies a potential revolution in

Artificial intelligence (AI) has revolutionized the pharmaceutical industry by providing innovative solutions in drug discovery, design, and manufacturing. In recent years, AI has become increasingly useful in drug manufacturing, offering several benefits such as increased speed, efficiency, accuracy, and cost-effectiveness. AI techniques, such as machine learning, natural language processing, and deep learning, are being used to mine vast amounts of data and extract meaningful insights that aid in drug development.

Digital transformation in the pharma industry involves the use of technology to streamline operations, enhance patient engagement, and improve the efficiency of clinical trials. It also involves the adoption of different methods like data analytics and integration, artificial intelligence, machine learning, cloud computing, and services, etc. to drive innovation and improve patient outcomes.

The pharmaceutical industry has been a pillar of healthcare for decades, but with the advancement of digital technologies, it is undergoing a major transformation. Digital technologies have the potenti

Nanomaterials have been one of the most exciting scientific and technical innovations of the past few decades. Due to their very high surface to volume ratios, they exhibit properties that can differ dramatically from those for the same material in bulk. This, and their ability to be designed and synthesized with multiple surface functionalities, has seen them used for a myriad of bespoke applications in industry and medicine.

Their medical applications span delivery systems for drugs, proteins and DNA/RNA to diagnostics, targeted cancer treatments, to theranostics. They have been used ver

Data can be used to analyze genomes, prescribe pharmaceuticals in the pharmaceutical and biotechnology industries, and a variety of other applications. Now that data has become "BIG DATA," analyzing it has become a whole new field of "Analytics and Data Science." The cost of genome structure analysis has decreased from ten million dollars in 2007 to one thousand dollars thanks to analytics. On the basis of big data analysis, a cancer treatment was prescribed. It can be used in a variety of industries and enterprises.

The pharmaceutical industry is in the midst of fundamental changes. The changes have been brought on by the increasing concerns over expiry of patents for major blockbuster drugs, weak product pipelines, heightened awareness of drug safety, globalisation, competition from generics and growing value considerations with regards to access to and reimbursement of new speciality therapeutics. These issues, and more, have forced top pharmaceutical companies to change their current course, in search of a stable and sustainable path that can help them maintain and improve their current profitability

Functional service has been ranked high among the buzz words of the clinical research industry. Both sponsor organisations and service providers are equally excited about the opportunities this model offers and the potentially win-win situation it provides to them. Sponsor organisations typically send individual protocol-related service RFPs (request for proposals) to CROs and follow-up with contract negotiations. Sponsors have realised the benefits of reduced oversight and contract management a complete functional service outsourcing model offers saving valuable time and resources.

The pharmaceutical market in Asia has undergone a paradigm shift in the past few years. The major global pharmaceutical companies have shifted their focus to this region to drive their revenue growth. Moreover, the domestic companies in Asia are also actively participating in the global drug development process. At present, the pharmaceutical market in the region is challenging due to changes in the competitive landscape, increasing R&D costs, and the need to develop the right marketing strategies.

In 2005, the pharmaceutical market in Asia was estimated to be around US$ 21 billion and is

There are many potential benefits that can be derived from IT outsourcing. Apart from cost savings, access to resources is also a driving force behind the outsourcing phenomena. With the right outsourcing partner enabling a flexible allocation of resources, IT projects can be scaled rapidly and affordably. Success or failure of outsourcing often has less to do with the provider and more to do with the customer. This is because discovery R&D organisations are rarely equipped to manage IT and have great difficulty specifying and implementing their goals. If any organisation has a poor track rec

Definition:The cold chain in the pharmaceutical industry refers to a temperature-controlled supply chain that ensures the integrity and efficacy of temperature-sensitive pharmaceutical products from the point of manufacture to the end-user. This specialized logistics system is designed to maintain specific temperature conditions throughout the entire distribution process, including storage, transportation, and handling.

Significance of the Cold Chain: The significance of the cold chain in the pharmaceutical industry cannot be overstated, especially when dealing with products that are sens

This article explores the transformative shift toward patient-centric clinical trials, emphasizing active patient involvement in study design, recruitment strategies, and the integration of Patient-Reported Outcomes (PROs). By prioritizing transparency, communication, and digital health technologies, patient-centric trials enhance engagement, streamline recruitment, and improve data quality. The approach holds the potential to accelerate drug development, but challenges like regulatory hurdles and data privacy concerns must be addressed collaboratively for widespread implementation.

Traditional clinical trials have long served as the cornerstone of medical research, providing essential evidence for evaluating the safety and efficacy of new interventions. However, these trials often encounter significant challenges, including inefficiencies, high costs, logistical complexities, and limited participant diversity. Post the COVID-19 pandemic era, a groundbreaking approach called decentralized clinical trials (DCTs) has emerged as the new normal, harnessing technological advancements to revolutionize the landscape of medical research. This article explores the principles, key

Medicine is the testament to the virtue of human innovation - a collective desire to reduce the burden of disease and an ever evolving journey to enhance the quality of human health. The origin of medicines can be traced back to ancient times when human began to use the natural resources to treat injuries and illness. Highly developed and documented evidences of medicinal practices comes from the world’s most ancient civilisations such as Egypt, India, China and Greece1. Traditional Chinese medicine2, which dates back more than 2,500 years, used a combination of herbs, acupuncture, and other

Cannabis plants contain a wide variety of complex compounds including phytocannabinoids, terpenoids and flavonoids, found mainly in the inflorescences. Major phytocannabinoids like CBD and ∆9-THC have beneficial effects on human health. It is well known that variations in their profiles are connected to growth, light quality, humidity, the use of pesticides, harvesting and especially post-harvesting, like improper drying procedures that can facilitate fungal and microbial growth. Mass spectrometry is the tool of choice for the analysis of all these biologically active compounds along with tha

The spleen is an organ found in all vertebrates. It is a large secondary lymphoid organ that primarily functions as a blood filter. The second spleen’s function is immune system surveillance. As a specialized immune organ, the spleen plays a significant role in innate and adaptive immunity. Specifically, the spleen is a crucial organ for peripheral immune tolerance, complementing central immune tolerance. Splenectomy in both study animals and humans results in overwhelming infections with especially, encapsulated bacteria [1]. On the opposite, supporting the immune system with an additional s

A countless number of proteins including growth factors receptors, and cytokines play a pivotal role during the onset and exacerbation of numerous human diseases including cancer, autoimmune and inflammatory disorders.1

Of these proteins, extracellular and membrane-associated proteins represent around 40% of human proteome and they play diversified roles including signal transduction, cell adhesion, cell-cell interaction, and solute transport. Accordingly, the vast majority (ca. 60%) of current therapeutic approaches; such as small molecule inhibitors, oligonucleotide agents and monoclonal